AddNeuroMed - The european collaboration for the discovery of novel biomarkers for alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 36-46

  Lovestone, Simon ^a   Francis, Paul ^a   Kloszewska, Iwona ^b   Mecocci, Patrizia ^c   Simmons, Andrew ^a   Soininen, Hilkka ^d   Spenger, Christian ^e   Tsolaki, Magda ^f   Vellas, Bruno ^g   Wahlund, Lars Olof ^e   Ward, Malcolm ^h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF PERUGIA   (Italy)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h Proteome Sciences   (United Kingdom)

Author keywords

A2M; Alzheimer's disease; Biomarkers; CFH; Plasma; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN;

ALZHEIMER DISEASE; CONFERENCE PAPER; DISEASE MARKER; FEASIBILITY STUDY; GENOMICS; HEALTH CARE ORGANIZATION; HUMAN; INTEGRATION; LIPIDOMICS; MEDICAL RESEARCH; METHODOLOGY; NEUROIMAGING; NONHUMAN; PROTEOMICS;

ANIMALIA;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COOPERATIVE BEHAVIOR; DISEASE PROGRESSION; EUROPE; HUMANS;

EID: 70449441004     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05064.x     Document Type: Conference Paper

References (34)

1. Lowin, A., M. Knapp & P. McCrone. 2001. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int. J. Geriatr. Psychiatry 16: 1143-1148.
2. Ferri, C.P., M. Prince, C. Brayne, et al. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
3. Mueller, S.G., M.W. Weiner, L.J. Thal, et al. 2005. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1: 55-66.
4. Lovestone, S., P. Francis & K. Strandgaard. 2007. Biomarkers for disease modification trials-the innovative medicines initiative and AddNeuroMed. J. Nutr. Health Aging 11: 359-361.
5. Holmes, C. & S. Lovestone. 2003. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 32: 200-204.
6. Schneider, L.S., K. Dagerman, Z. Shaikh & P. Insel. 2008. No secular trend and high variability for ADAS-cog change among placebo groups from clinical trials. Alzheimer's Dement. 4(4; supplement1), T167.
7. Jones, R.W., E. Schwam, D. Wilkinson, et al. 2009. Rates of cognitive change in alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis. Assoc. Disord. Jun 25 [Epub ahead of print].
8. NIH Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95.
9. Burns,A., P. Luthert,R. Levy, et al. 1990. Accuracy of clinical diagnosis of Alzheimer's disease. BMJ 301: 1026.
10. Alzheimers Assoc, Natl Inst Aging. 1998. Consensus report of the Working Group on: "Molecular and BiochemicalMarkers of Alzheimer's Disease." Neurobiol. Aging 19: 109-116.
11. Vellas, B., S. Andrieu, C. Sampaio & G. Wilcock. 2007. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 6: 56-62.
12. Simmons, A., E. Westman, S. Muehlboeck, et al. for the AddNeuroMed consortium. 2009. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann. N. Y. Acad. Sci. Biomarkers in Brain Disease. 1180: 47-55.
13. Anonymous. 1966. Pink spot in schizophrenia. Br. Med. J. 1: 119.
14. Hye, A., S. Lynham, M. Thambisetty, et al. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11): 3042-3050.
15. Jones, R.S. & A.D.Waldman. 2004. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 26: 488-495.
16. Thambisetty, M., A. Hye, C. Foy, et al. 2008. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 255: 1712-1720.
17. De, S.B. & L.F. Van. 1993. Alpha 2-macroglobulin and subacute-phase responses in Alzheimer's disease. Immunol. Today 14: 143-144.
18. Hyman, B.T., D.K. Strickland & G.W. Rebeck. 1994. Alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Relationship to apolipoprotein E and role in Alzheimer disease senile plaques. Ann. N. Y. Acad. Sci. 737: 88-95.
19. Blacker, D., M.A. Wilcox, N.M. Laird, et al. 1998. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19: 357-360.
20. Bertram, L., M. McQueen, K. Mullin, et al. 2005. The Alz Gene Database. Alzheimer Research Forum. Available at: http://www.alzgene.org.
21. Bonifati, D.M. & U. Kishore. 2007. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 44: 999-1010.
22. Skaper, S.D. 2007. The brain as a target for inflammatory processes and neuroprotective strategies. Ann. N. Y. Acad. Sci. 1122: 23-34.
23. Thakkinstian, A., P. Han, M. Mc Evoy, et al. 2006. Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration. Hum. Mol. Genet. 15: 2784-2790. (Pubitemid 44400405)
24. Anderson, D.H., K.C. Talaga, A.J. Rivest, et al. 2004. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp. Eye Res. 78: 243-256.
25. Yoshida, T., K. Ohno-Matsui, S. Ichinose, et al. 2005. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J. Clin. Invest. 115: 2793-2800.
26. Luibl, V., J.M. Isas, R. Kayed, et al. 2006. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Invest. 116: 378-385.
27. Swaroop, A., K.E. Branham, W. Chen & G. Abecasis. 2007. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum. Mol. Genet. 16(SpecNo. 2): R174-R182.
28. Hamilton, G., P. Proitsi, J. Williams, et al. 2007. Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease. Neuromolecular Med. 9: 331-334.
29. Le Fur, I., G. Laumet, F. Richard, et al. 2008. Association study of the CFH Y402H polymorphism with Alzheimer's disease. Neurobiol. Aging. Apr 21 [Epub ahead of print].
30. Zetterberg, M., S. Landgren, M.E. Andersson, et al. 2008. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B: 720-726.
31. Cutler, P., E.L. Akuffo, W.M. Bodnar, et al. 2008. Proteomic identification and early validation of complement 1 inhibitor and pigment-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics - Clin. Appl. 2: 467-477.
32. Akuffo, E.L., J.B. Davis, S.M. Fox, et al. 2008.The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13: 618-636.
33. Ray, S., M. Britschgi, C. Herbert, et al. 2007. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13: 1359-1362.
34. Marksteiner, J., G. Kemmler, E.M.Weiss, et al. 2009. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging. Apr 21 [Epub ahead of print].